Forian (NASDAQ:FORA) reported quarterly sales of $6.50 million which beat the analyst consensus estimate of $6.18 million by 5.18 percent. This is a 42.92 percent increase over sales of $4.55 million the same period last year.
Forian Q2 Sales $6.50M Beat $6.18M Estimate
Forian (NASDAQ:FORA) reported quarterly sales of $6.50 million which beat the analyst consensus estimate of $6.18 million by 5.18 percent. This is a 42.92 percent increase over sales of $4.55 million the same period
Related Posts
JP Morgan Maintains Overweight on RxSight, Lowers Price Target to $20
March 7, 9:22 AM
JP Morgan analyst Robbie Marcus maintains RxSight (NASDAQ:RXST) with a Overweight and lowers the price target from $22 to $20.
Eli Lilly Cracks Down on Counterfeit Mounjaro Wight Loss and Diabetes Drugs, Sues Lawsuit Against Clinics
September 20, 9:18 AM
Eli Lilly And Co (NYSE: LLY) has taken